Literature DB >> 25788518

Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning.

Corina Anastasaki1, Albert S Woo2, Ludwine M Messiaen3, David H Gutmann4.   

Abstract

Neurofibromatosis type 1 (NF1) is a common autosomal dominant neurologic condition characterized by significant clinical heterogeneity, ranging from malignant cancers to cognitive deficits. Recent studies have begun to reveal rare genotype-phenotype correlations, suggesting that the specific germline NF1 gene mutation may be one factor underlying disease heterogeneity. The purpose of this study was to define the impact of the germline NF1 gene mutation on brain neurofibromin function relevant to learning. Herein, we employ human NF1-patient primary skin fibroblasts, induced pluripotent stem cells and derivative neural progenitor cells (NPCs) to demonstrate that NF1 germline mutations have dramatic effects on neurofibromin expression. Moreover, while all NF1-patient NPCs exhibit increased RAS activation and reduced cyclic AMP generation, there was a neurofibromin dose-dependent reduction in dopamine (DA) levels. Additionally, we leveraged two complementary Nf1 genetically-engineered mouse strains in which hippocampal-based learning and memory is DA-dependent to establish that neuronal DA levels and signaling as well as mouse spatial learning are controlled in an Nf1 gene dose-dependent manner. Collectively, this is the first demonstration that different germline NF1 gene mutations differentially dictate neurofibromin function in the brain.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25788518      PMCID: PMC4553714          DOI: 10.1093/hmg/ddv103

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  39 in total

1.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.

Authors:  T N Basu; D H Gutmann; J A Fletcher; T W Glover; F S Collins; J Downward
Journal:  Nature       Date:  1992-04-23       Impact factor: 49.962

2.  Treatment of ADHD in neurofibromatosis type 1.

Authors:  Victor-F Mautner; Lan Kluwe; Sarang D Thakker; Robert A Leark
Journal:  Dev Med Child Neurol       Date:  2002-03       Impact factor: 5.449

3.  Activation of EGFP expression by Cre-mediated excision in a new ROSA26 reporter mouse strain.

Authors:  X Mao; Y Fujiwara; A Chapdelaine; H Yang; S H Orkin
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

Review 4.  The pathoetiology of neurofibromatosis 1.

Authors:  Eeva-Mari Jouhilahti; Sirkku Peltonen; Anthony M Heape; Juha Peltonen
Journal:  Am J Pathol       Date:  2011-03-31       Impact factor: 4.307

5.  Modeling familial Alzheimer's disease with induced pluripotent stem cells.

Authors:  Takuya Yagi; Daisuke Ito; Yohei Okada; Wado Akamatsu; Yoshihiro Nihei; Takahito Yoshizaki; Shinya Yamanaka; Hideyuki Okano; Norihiro Suzuki
Journal:  Hum Mol Genet       Date:  2011-09-07       Impact factor: 6.150

6.  Elevated risk for MPNST in NF1 microdeletion patients.

Authors:  T De Raedt; H Brems; P Wolkenstein; D Vidaud; S Pilotti; F Perrone; V Mautner; S Frahm; R Sciot; E Legius
Journal:  Am J Hum Genet       Date:  2003-03-26       Impact factor: 11.025

7.  Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice.

Authors:  Jacquelyn A Brown; Ryan J Emnett; Crystal R White; Carla M Yuede; Sara B Conyers; Karen L O'Malley; David F Wozniak; David H Gutmann
Journal:  Hum Mol Genet       Date:  2010-09-07       Impact factor: 6.150

8.  Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues.

Authors:  C I Brannan; A S Perkins; K S Vogel; N Ratner; M L Nordlund; S W Reid; A M Buchberg; N A Jenkins; L F Parada; N G Copeland
Journal:  Genes Dev       Date:  1994-05-01       Impact factor: 11.361

Review 9.  Clinical and genetic aspects of neurofibromatosis 1.

Authors:  Kimberly Jett; Jan M Friedman
Journal:  Genet Med       Date:  2010-01       Impact factor: 8.822

10.  p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas.

Authors:  Valentina Pinna; Valentina Lanari; Paola Daniele; Federica Consoli; Emanuele Agolini; Katia Margiotti; Irene Bottillo; Isabella Torrente; Alessandro Bruselles; Caterina Fusilli; Anna Ficcadenti; Sara Bargiacchi; Eva Trevisson; Monica Forzan; Sandra Giustini; Chiara Leoni; Giuseppe Zampino; Maria Cristina Digilio; Bruno Dallapiccola; Maurizio Clementi; Marco Tartaglia; Alessandro De Luca
Journal:  Eur J Hum Genet       Date:  2014-11-05       Impact factor: 4.246

View more
  45 in total

1.  NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.

Authors:  Joseph A Toonen; Corina Anastasaki; Laura J Smithson; Scott M Gianino; Kairong Li; Robert A Kesterson; David H Gutmann
Journal:  Hum Mol Genet       Date:  2016-02-16       Impact factor: 6.150

2.  Neurofibromatosis Type 1 Implicates Ras Pathways in the Genetic Architecture of Neurodevelopmental Disorders.

Authors:  Jessica A Kaczorowski; Taylor F Smith; Amanda M Shrewsbury; Leah R Thomas; Valerie S Knopik; Maria T Acosta
Journal:  Behav Genet       Date:  2020-02-05       Impact factor: 2.805

3.  Characterization of early communicative behavior in mouse models of neurofibromatosis type 1.

Authors:  Susan E Maloney; Krystal C Chandler; Corina Anastasaki; Michael A Rieger; David H Gutmann; Joseph D Dougherty
Journal:  Autism Res       Date:  2017-08-26       Impact factor: 5.216

Review 4.  Constructing and Deconstructing Cancers using Human Pluripotent Stem Cells and Organoids.

Authors:  Ryan C Smith; Viviane Tabar
Journal:  Cell Stem Cell       Date:  2018-12-20       Impact factor: 24.633

5.  Exploring the genetic basis for clinical variation in neurofibromatosis type 1.

Authors:  David H Gutmann
Journal:  Expert Rev Neurother       Date:  2016-05-30       Impact factor: 4.618

Review 6.  Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.

Authors:  Morgan E Freret; David H Gutmann
Journal:  J Neurosci Res       Date:  2018-04-28       Impact factor: 4.164

Review 7.  Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.

Authors:  Robert Listernick; Rosalie E Ferner; Grant T Liu; David H Gutmann
Journal:  Ann Neurol       Date:  2007-03       Impact factor: 10.422

Review 8.  Dopaminergic dysfunction in neurodevelopmental disorders: recent advances and synergistic technologies to aid basic research.

Authors:  J Elliott Robinson; Viviana Gradinaru
Journal:  Curr Opin Neurobiol       Date:  2017-08-30       Impact factor: 6.627

9.  Immortalization of human normal and NF1 neurofibroma Schwann cells.

Authors:  Hua Li; Lung-Ji Chang; Debbie R Neubauer; David F Muir; Margaret R Wallace
Journal:  Lab Invest       Date:  2016-09-12       Impact factor: 5.662

Review 10.  Contextual signaling in cancer.

Authors:  Laura J Smithson; Corina Anastasaki; Ran Chen; Joseph A Toonen; Sidney B Williams; David H Gutmann
Journal:  Semin Cell Dev Biol       Date:  2016-06-03       Impact factor: 7.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.